Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5195803 | 0.88 | MEN1 (0.31) | — | |
| SCHEMBL643093 | 0.85 | KDM4E (0.37) | FFAR3 | |
| SCHEMBL1583637 | 0.83 | ALDH1A1 (0.30) | — | |
| SCHEMBL154523 | 0.83 | ALDH1A1 (0.30) | — | |
| SCHEMBL1583472 | 0.83 | ALDH1A1 (0.30) | — | |
| SCHEMBL1015506 | 0.82 | — | — | |
| SCHEMBL27190694 | 0.81 | DGAT1 (0.30) | — | |
| SCHEMBL1955216 | 0.80 | — | — | |
| SCHEMBL1584220 | 0.80 | — | — | |
| SCHEMBL5540046 | 0.80 | FFAR3 (0.36) | FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149447-B2 | Lysine specific demethylase-1 inhibitors and their use | ORYZON GENOMICS S.A. (ES) | 2015-10-06 | — | — | US | disclosed |
| US-8946296-B2 | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use | ORYZON GENOMICS S.A. (ES) | 2015-02-03 | — | — | US | disclosed |
| US-8859555-B2 | Lysine Specific Demethylase-1 inhibitors and their use | ORYZON GENOMICS S.A. (ES) | 2014-10-14 | — | — | US | disclosed |
| US-20140213657-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2014-07-31 | — | — | US | disclosed |
| WO-2013067302-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| US-20120283266-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2012-11-08 | — | — | US | disclosed |
| US-20120264823-A1 | SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS S.A. | 2012-10-18 | — | — | US | disclosed |
| WO-2011131697-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011042217-A1 | SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011035941-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283266-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | JMJD6, KDM3A, KDM1A | FFAR3 1129/4885 |
| US-20120264823-A1 | SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | CBR1, CNR1, CBR3 | FFAR3 1014/4885 |
| US-20140213657-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | KDM1A, KDM1B, KDM3A | FFAR3 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.